CliniOps worked very closely with all its customers from 2016, and that has already started paying dividends from early January. We started the year by signing up a few repeat customers and a few annual extensions. CliniOps now supports studies in Mozambique and Swaziland, among others.
During our initial interaction with our customers, as part of the ‘Study Setup’ activity, CliniOps Global Delivery team engages closely with the client study team including the site coordinators. The purpose of this interaction is to clearly understand the processes and the workflow that are usually followed at their site level. Some of these activities are usually very unique to each site based on parameters like country specific regulatory requirements, local culture & taboos, technology adoption, computer literacy, network connectivity et. al. This step is of paramount importance that makes it possible for us to configure our eSource application to closely align with the processes followed on the ground. Introducing a new technology is not always easy, especially in this space where technology adoption is relatively slow. But fortunately for us, we have been able to overcome this and turn our clients into Happy Customers.
Quarterly Updates Jan – Mar 2017
BMJ Journals featured CliniOps in its report
CliniOps mentioned among commercial eSource solutions in a publication titled ‘Open-source mobile digital platform for clinical trial data collection in low-resource settings’ sponsored by Novartis Institutes for BioMedical Research (NIBR), and published by British Medical Journals, on January 6, 2017
Washington University School of Medicine blogs CliniOps eSource solution
The DOLF (Death to Onchocerciasis and Lymphatic Filariasis) project team, supported by the Bill and Melinda Gates Foundation, highlights the value proposition of CliniOps eSource solution in its 30,000+ participant global study, across 5 countries, in extremely resource poor settings.
CliniOps CEO invited to speak at the Society of Physician Entrepreneurs
The Society of Physician Entrepreneurs (SOPE) is a global biomedical and healthcare innovation network, with a vision to create a global community that accelerates medical innovation to patients around the world. CliniOps CEO was invited to speak at a SoPE event titled ‘Technology powering Clinical Research and Education’, in San Francisco, Jan 19, 2017
Innovation That Matters
Zero Data Loss Inspite of Extreme Connectivity Challenges
Point-of-care network access is a constant challenge where the patient-doctor interaction happens. Most US hospitals have very stringent network setup that prohibits on-the-go network access, especially for ambulatory services where the doctor goes from bed to bed, to see patients. Network access at the point of care is an even bigger challenge at resource poor settings in the emerging world countries.
CliniTrial was used in a community based mass drug administration study to collect safety data from across several countries in extreme resource poor areas with limited internet availability. 165 study users collected data in 4 different languages, across 24,000 participants with over 190,000 visits, resulting in 4,500,000 data points in a database with 3,000 variables, in just 5 months. Data was synced regularly through a secured server either using 3G local Enterprise internet providers (DigiCel in Haiti; Airtail in India) or satellite wifi (IndoSat in Indonesia; Northern Axcess in PNG). There were several network connectivity challenges but inspite of all these limitations, CliniOps application worked seamless and ensured complete data upload even in such conditions.
Highly Configurable Platform to Also Support Alternative Medicines
Some clinical trials are run to compare the effects of mainstream medicines with that of alternative medicines, or a combination thereof. Configuring such trials demand a highly configurable platform to adjust to such protocol requirements.
CliniOps had a unique opportunity to use our eSource platform in a Hepatitis B and Type II Diabetes trial, where we compare the outcome of interventions from main stream medicines with alternative medicines. Customer was highly impressed with our platform because of its simplicity to use and its ability to adapt to such unique study specific protocol requirements.